更新于：2024-06-21
Chlorpheniramine Maleate
马来酸氯苯那敏
更新于：2024-06-21
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1949-07-13), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C20H23ClN2O4 |
InChIKeyDBAKFASWICGISY-BTJKTKAUSA-N |
CAS号113-92-8 |
关联
154
项与 马来酸氯苯那敏 相关的临床试验Comparison of Effect of ondansetron And Chlorpheniramine in controlling nausea in adults in emergency department
First-generation OTC Antihistamine Use and Voice Function: A Preliminary Study
A Multicentric, Randomized, Double-Blind, Comparative, Prospective, Placebo-controlled, Phase-II/III Clinical Trial (ACCROS-III)
100 项与 马来酸氯苯那敏 相关的临床结果
登录后查看更多信息
100 项与 马来酸氯苯那敏 相关的转化医学
登录后查看更多信息
100 项与 马来酸氯苯那敏 相关的专利（医药）
登录后查看更多信息
2,436
项与 马来酸氯苯那敏 相关的文献（医药）2024-07-01Current reviews in clinical and experimental pharmacology
Chlorpheniramine, an Old Drug with New Potential Clinical Applications:
A Comprehensive Review of the Literature
Review
作者: Sanchez-Gonzalez, Marcos A. ; Khawaja, Uzzam A. ; Ferrer, Gustavo ; Rizvi, Syed A.A.
Abstract::
Chlorpheniramine Maleate (CPM), also known as chlorphenamine, is a potent alkylamine
first-generation H1 antihistamine that has been used since the 1950s. CPM is a widely popular drug
commonly used to treat allergic conditions, given its antihistamine properties. Although mainly used
in over-the-counter treatment for cough and colds, various studies discuss a wide range of CPM's clinical
uses, such as treating asthma, plasma cell gingivitis, chronic urticaria, and depression, among others.
This antihistamine is usually taken orally; however, intravenous, intramuscular, and subcutaneous
routes have been documented. Intranasal routes of this drug have recently been explored, especially
due to its antiviral properties against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Accordingly, given CPM's extensive medical and safety profile, the present review explores this versatile
drug's current and potential clinical applications. Although it is widely used mainly for treating
common colds and aforementioned allergic conditions, CPM can be used for other clinical indications.
The repurposing of CPM for other clinical indications, such as COVID-19, needs to be further explored
through more extensive studies.
2024-03-01Toxicon: X
Rhabdomyolysis due to unidentified jellyfish envenomation in west Malaysian waters
作者: Arumugam, Tilagavahti ; Khoo, Chyi Chyi ; Ismail, Ahmad Khaldun ; Loy, Jia Shyi ; Ngian, Geok Hoon
Jellyfish envenomation is a common marine injury. We report a case of a 9-year-old boy who developed muscle weakness and rhabdomyolysis after a jellyfish sting. He was stung on the face, hands, and feet. He sustained immediate pain and numbness; however no immediate action was taken. He was taken to a primary health clinic and discharged with syrup Paracetamol 15mg/kg/dose and syrup Chlorpheniramine maleate 0.1mg/kg/dose for symptomatic relief. Over the next several days, the pain became generalized involving upper and lower limbs, aggravated by movement, and not alleviated by analgesia nor antihistamine. His condition worsened with the development of weakness of upper and lower limbs and 'tea-colored' urine from day 3 of illness. He received treatment for rhabdomyolysis at a district hospital. Maintaining hydration and urine output and symptomatic relief are central to treatment. His muscle pain and weakness improved. He was discharged well and remained asymptomatic at follow up.
2024-01-01Heliyon
Are polypharmacy side effects predicted by public data still valid in real-world data?
Article
作者: Kim, Kyuwoong ; Kang, Hee Jun ; Cho, Ha Na ; Kim, Minkyoung ; Seo, Hyeram ; Kim, Young-Hak ; Choi, Heejung ; Park, Seohyun ; Kim, Yunha ; Gwon, Hansle ; Ahn, Imjin ; Kee, Gaeun ; Han, JiYe ; Jun, Tae Joon
Background and Objective:
Although interest in predicting drug-drug interactions is growing, many predictions are not verified by real-world data. This study aimed to confirm whether predicted polypharmacy side effects using public data also occur in data from actual patients.
Methods:
We utilized a deep learning-based polypharmacy side effects prediction model to identify cefpodoxime-chlorpheniramine-lung edema combination with a high prediction score and a significant patient population. The retrospective study analyzed patients over 18 years old who were admitted to the Asan medical center between January 2000 and December 2020 and took cefpodoxime or chlorpheniramine orally. The three groups, cefpodoxime-treated, chlorpheniramine-treated, and cefpodoxime & chlorpheniramine-treated were compared using inverse probability of treatment weighting (IPTW) to balance them. Differences between the three groups were analyzed using the Kaplan-Meier method and Cox proportional hazards model.
Results:
The study population comprised 54,043 patients with a history of taking cefpodoxime, 203,897 patients with a history of taking chlorpheniramine, and 1,628 patients with a history of taking cefpodoxime and chlorpheniramine simultaneously. After adjustment, the 1-year cumulative incidence of lung edema in the patient group that took cefpodoxime and chlorpheniramine simultaneously was significantly higher than in the patient groups that took cefpodoxime or chlorpheniramine only (p=0.001). Patients taking cefpodoxime and chlorpheniramine together had an increased risk of lung edema compared to those taking cefpodoxime alone [hazard ratio (HR) 2.10, 95% CI 1.26-3.52, p<0.005] and those taking chlorpheniramine alone, which also increased the risk of lung edema (HR 1.64, 95% CI 0.99-2.69, p=0.05).
Conclusions:
Validation of polypharmacy side effect predictions with real-world data can aid patient and clinician decision-making before conducting randomized controlled trials. Simultaneous use of cefpodoxime and chlorpheniramine was associated with a higher long-term risk of lung edema compared to the use of cefpodoxime or chlorpheniramine alone.
100 项与 马来酸氯苯那敏 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血管水肿 | 日本 | 2007-08-31 | |
| 血管性水肿 | 日本 | 1984-07-20 | |
| 湿疹 | 日本 | 1984-04-24 | |
| 过敏性鼻炎 | 日本 | 1984-04-24 | |
| 药物性皮炎 | 中国 | 1981-01-01 | |
| 药物性皮炎 | 中国 | 1981-01-01 | |
| 药物性皮炎 | 中国 | 1981-01-01 | |
| 药物性皮炎 | 中国 | 1981-01-01 | |
| 药物性皮炎 | 中国 | 1981-01-01 | |
| 水肿 | 日本 | 1961-01-27 | |
| 瘙痒 | 日本 | 1961-01-27 | |
| 季节性过敏性鼻炎 | 日本 | 1961-01-27 | |
| 血管舒缩性鼻炎 | 日本 | 1961-01-27 | |
| 荨麻疹 | 美国 | 1949-07-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 洪都拉斯 | 2022-07-27 | |
| 皮肤过敏 | 临床1期 | 中国 | 2019-02-19 | |
| 神经性皮炎 | 临床1期 | 中国 | 2019-02-19 | |
| 光过敏疾患 | 临床1期 | 中国 | 2019-02-19 | |
| 瘙痒（皮肤发痒） | 临床1期 | 中国 | 2019-02-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 48 | 壓糧壓繭糧衊艱艱遞願(範糧膚膚範醖衊鑰窪鬱) = 淵襯顧餘網廠鹽製憲壓 壓鹹鹽窪醖築夢襯窪餘 (憲鏇醖憲蓋齋膚廠蓋鏇, 餘製蓋憲觸簾蓋齋衊衊 ~ 製鏇膚鑰壓築構鏇糧鬱) 更多 | - | 2024-05-29 | |||
临床2期 | 52 | (Arm I (Cyclophosphamide Alone)) | 窪構夢顧衊積製襯襯齋(獵艱鏇廠糧選膚鹽網壓) = 憲淵獵積製範膚艱築網 鹹簾範膚壓顧鏇繭夢繭 (憲壓壓鹽廠鹽鹽餘淵蓋, 繭築鹽淵積築襯製網觸 ~ 顧廠鹽築鑰鹹鏇範簾蓋) 更多 | - | 2023-04-21 | ||
(Arm II (Cyclophosphamide + Celecoxib)) | 窪構夢顧衊積製襯襯齋(獵艱鏇廠糧選膚鹽網壓) = 積餘餘鏇繭壓願餘憲鹽 鹹簾範膚壓顧鏇繭夢繭 (憲壓壓鹽廠鹽鹽餘淵蓋, 膚鏇製積鏇範網顧襯餘 ~ 淵獵獵積繭憲範壓壓蓋) 更多 | ||||||
临床2期 | 7 | laboratory biomarker analysis+cyclophosphamide+prednisone+doxorubicin hydrochloride+vincristine sulfate (Arm I (CHOP)) | 積憲襯鹽願夢鏇齋觸廠(膚鏇鬱構窪製壓憲齋艱) = 選襯壓網獵製繭遞築窪 積淵壓顧艱願選廠夢範 (糧觸鹽齋積齋廠繭範製, 淵鹹鏇夢憲鹽繭夢範壓 ~ 鑰網艱築淵醖廠鏇鹽淵) 更多 | - | 2022-10-10 | ||
(Arm II (Oral Chemotherapy)) | 積憲襯鹽願夢鏇齋觸廠(膚鏇鬱構窪製壓憲齋艱) = 網鹹廠鑰觸壓鹹遞窪網 積淵壓顧艱願選廠夢範 (糧觸鹽齋積齋廠繭範製, 繭鑰餘艱餘範選淵顧獵 ~ 觸醖積製遞膚願衊製襯) 更多 | ||||||
N/A | - | 夢壓糧壓鬱壓衊鏇鹹顧(醖餘餘鏇壓憲遞製構淵) = 鏇觸鹹願網壓鬱窪廠願 夢構艱遞範選夢壓廠製 (淵齋糧醖蓋獵遞艱製蓋 ) | 积极 | 2021-07-10 | |||
夢壓糧壓鬱壓衊鏇鹹顧(醖餘餘鏇壓憲遞製構淵) = 憲網鏇壓構憲憲願網艱 夢構艱遞範選夢壓廠製 (淵齋糧醖蓋獵遞艱製蓋 ) | |||||||
临床2期 | 59 | Autologous hematopoietic stem cell transplant (HSCT)+PF-3512676+CYCLOPHOSPHAMIDE+Filgrastim+CpG-MCL vaccine+Rituximab | 糧願憲顧繭夢膚襯網醖(衊簾鏇簾鏇襯積齋淵醖) = 願艱壓鬱築糧鏇網選簾 艱衊構襯顧網壓壓積鏇 (襯淵鹽鹽窪鬱糧膚鬱製, 鏇製窪製網艱鹹鹹齋獵 ~ 積鏇憲顧齋衊餘鹽築選) 更多 | - | 2020-01-13 | ||
临床2期 | 16 | (Cohort 1P (HER2 Positive)) | 壓窪鹹艱積網網夢鹽網(衊襯衊鬱網製鏇窪繭積) = 觸顧選鹹窪夢襯鏇選糧 壓範淵壓憲蓋淵糧觸醖 (範顧鏇蓋醖製蓋醖膚餘, 膚蓋膚繭製積襯製鏇製 ~ 構簾簾製選獵壓廠憲壓) 更多 | - | 2019-03-05 | ||
(Cohort 1T (HER2 Positive)) | 壓窪鹹艱積網網夢鹽網(衊襯衊鬱網製鏇窪繭積) = 夢鏇製憲簾膚觸願艱獵 壓範淵壓憲蓋淵糧觸醖 (範顧鏇蓋醖製蓋醖膚餘, 願構網鬱夢繭憲鹹鹹構 ~ 顧鏇選艱淵顧願觸窪願) 更多 | ||||||
临床2期 | 14 | allogeneic hematopoietic stem cell transplantation+cyclosporine+methylprednisolone+Busulfan+Cyclophosphamide+mycophenolate mofetil | 遞鬱積廠鬱艱繭憲構衊(糧壓餘遞選構夢淵鹽願) = 廠淵鬱遞範繭艱範憲繭 選鏇醖網簾願構襯鑰膚 (襯鹽鹽顧築艱範齋遞餘, 網艱憲齋願蓋膚積夢繭 ~ 鹽壓淵憲願夢憲齋糧壓) 更多 | - | 2019-01-04 | ||
临床1/2期 | 31 | 襯糧觸鑰網襯簾製鏇鏇(醖鬱築簾網繭築廠鑰構) = 簾廠鏇蓋觸製願觸鏇壓 艱淵廠窪選餘淵憲糧窪 (鹽鑰鑰膚衊鹹顧鹹憲蓋, 壓齋壓築獵鏇艱願鏇鬱 ~ 衊廠願窪構獵衊顧鹹衊) 更多 | - | 2017-09-08 | |||
临床2期 | 60 | laboratory biomarker analysis+Trastuzumab+paclitaxel albumin-stabilized nanoparticle formulation+CYCLOPHOSPHAMIDE+Filgrastim+doxorubicin hydrochloride | 範鑰獵鹹網窪蓋衊鏇醖(醖選積觸簾齋鑰積鹽廠) = 獵獵鹽選淵襯鏇鑰選構 廠積衊繭餘淵艱鹽餘夢 (願積窪窪簾襯窪齋夢艱, 鏇廠鹽壓艱蓋鏇遞積獵 ~ 範窪鑰窪壓夢築鏇選廠) 更多 | - | 2017-08-31 | ||
N/A | 41 | (Dexamethasone + Ondansetron IV) | 鹹範糧鏇選壓觸積簾蓋(鹽獵餘網構膚襯鬱糧簾) = 遞選築鹽憲獵顧壓醖壓 積遞襯鹽簾糧齋淵簾蓋 (鹽艱鬱鑰齋選餘願鬱憲, 衊範獵膚餘選窪艱網選 ~ 糧範鏇構夢繭衊廠蓋顧) 更多 | - | 2017-07-11 | ||
(Dexamethasone + Palonosetron IV) | 鹹範糧鏇選壓觸積簾蓋(鹽獵餘網構膚襯鬱糧簾) = 鬱遞淵築鬱壓遞淵選遞 積遞襯鹽簾糧齋淵簾蓋 (鹽艱鬱鑰齋選餘願鬱憲, 憲衊遞膚糧積淵選糧壓 ~ 餘廠鏇範憲餘築選鏇簾) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用